WPI 2287 (Propafenone Hydrochloride Extended-Release 425 mg)
Pill with imprint WPI 2287 is White, Capsule-shape and has been identified as Propafenone Hydrochloride Extended-Release 425 mg. It is supplied by Actavis Pharma, Inc..
Propafenone is used in the treatment of atrial fibrillation; ventricular tachycardia; wolff-parkinson-white syndrome; atrial flutter and belongs to the drug class group I antiarrhythmics. Risk cannot be ruled out during pregnancy. Propafenone 425 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 2287
Propafenone Hydrochloride Extended-Release
- Imprint
- WPI 2287
- Strength
- 425 mg
- Color
- White
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Group i antiarrhythmics
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Actavis Pharma, Inc.
- National Drug Code (NDC)
- 00591-2287
More about propafenone
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 60 Reviews
- Drug class: group I antiarrhythmics
- FDA Alerts (1)
Consumer resources
- Patient Information
- Propafenone (Advanced Reading)
- Propafenone Tablets
- Propafenone Sustained-Release Capsules
- Other brands
- Rythmol, Rythmol SR
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.